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In this multi-author work, Metten-
leiter and Sobrino have compiled 10 
chapters that describe what is cur-
rently known about the molecular bi-
ology of some of the most interesting 
viruses of veterinary importance, from 
the tiny circovirus of pigs (1,800 nt of 
single-stranded DNA) to the highly 
complex African swine fever virus 
(≈200,000 nt pairs of double-stranded 
DNA). It is ﬁ  tting that the ﬁ  rst chapter 
describes foot-and-mouth disease vi-
rus, which was the ﬁ  rst animal virus 
to be described by Loefﬂ  er and Fro-
sch, who worked in Griefswald-Insel 
Riems, where Mettenleiter is cur-
rently the president of the Friedrich-
Loefﬂ  er Institut. All 10 chapters are 
written by experts in their respective 
ﬁ  elds. Mettenleiter is a coauthor for a 
chapter about herpesviruses, whereas 
Sobrino is a coauthor for one on foot-
and-mouth disease virus. Polly Roy 
wrote a chapter about bluetongue 
virus, one of the major threats to the 
livestock industry worldwide, which 
recently emerged in Europe, perhaps 
because global warming has allowed 
the Culicoides vector to survive and 
overwinter. Another chapter is about 
Hendra and Nipah viruses, which are 
newly emerging in Southeast Asia and 
Australia. There are also informative 
chapters on arteriviruses, coronavirus-
es, and pestiviruses. Finally, in 1 chap-
ter, Hans-Dieter Klenk and colleagues 
write about viruses of birds, includ-
ing avian inﬂ  uenza. They discuss the 
molecular mechanism of pathogenesis 
and host range for the virus everyone 
fears may give rise to the next inﬂ  u-
enza pandemic.
The book would have been im-
proved by including a chapter on 
paramyxoviruses, of which rinder-
pest virus of cattle and Newcastle 
disease virus of birds are 2 important 
examples. But, overall, this compila-
tion is excellent and is rounded off by 
a scholarly and provocative epilogue 
about animal virology by Esteban 
Domingo and Marian C. Horzinek. It 
is almost worth buying the book for 
these 10 pages alone.
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Reviewing and summarizing the 
treatment of HIV disease and its com-
plications is a daunting task. Writing 
a textbook incorporating the rapidly 
evolving treatments and management 
strategies is even more difﬁ  cult.  In 
this third edition of AIDS Therapy, 
the authors have combined the efforts 
of international experts to fulﬁ  ll this 
goal. As with every textbook, refer-
ences are a little outdated; few refer-
ences are more recent than 2006. The 
addition of online access to updates 
will possibly alleviate this problem, 
although the online version still lists 
the Department of Health and Human 
Services guidelines for antiretroviral 
use from October 2006.
Excellent chapters cover the sero-
logic diagnosis of HIV disease, prima-
ry care in industrialized and resource-
limited countries, strategic use of 
antiretroviral agents, immune-based 
therapies, and special clinical settings. 
Although the management of pregnant 
HIV-positive patients is discussed, no 
individual coverage of pediatrics is 
provided.
The text provides comprehensive 
reviews of each antiretroviral agent, 
summarizing pharmacology, adverse 
reactions, and clinical uses, and ex-
tensively reviewing major trials for 
each agent. For some of these agents, 
this represents a historical review of 
monotherapy without practical appli-
cation. For example, a full chapter is 
devoted to zalcitabine, an agent that 
was discontinued in June 2006. For 
antiretroviral agents, the best summa-
ry, referred to as “recommendations 
for use,” is included in the last section 
of each drug chapter. 
Individual chapters describe op-
portunistic infections and malignan-
cies, including their diagnosis, thera-
py, and prevention of these diseases. 
Variability in the length of these chap-
ters does not always correlate with the 
importance of these processes. The 
inclusion of multiple charts and al-
gorithms provides a useful approach 
to diagnosis and management. The 
last major section of the text provides 
approaches to speciﬁ  c syndromes in-
cluding the major problems in patient 
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